Overactive Bladder Treatment Market Report with Competitive Analysis

Overactive Bladder Treatment Market Report with Competitive Analysis

Overactive Bladder Treatment Market Overview:

The market for overactive bladder treatment is expected to grow at a CAGR of 2.9 percent from USD 3.63 billion in 2017 to USD 4.19 billion by 2022. With only a few regional and national companies, this market is highly consolidated. In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (United States) led the overactive bladder therapy market, accounting for roughly 60% to 70% of the total market share.

In 2016, Astellas Pharma, Inc. dominated the global market for overactive bladder treatments. VESIcare (solifenacin) and BETMIGA (mirabegron) are two proprietary medications offered by the firm. Due to its high efficacy relative to other oral treatments, VESIcare is the company's blockbuster medicine, allowing it to maintain its leadership position in the overactive bladder therapy market. Astellas' "Creating Innovation" strategy, which is backed by the company's R&D division, aids in the identification of new therapeutic areas as well as innovative solutions for current ones. Its strong pipeline is the consequence of years of heavy R&D investment. Astellas has 47 molecular and biological entities in the clinical pipeline as of April 2017.

Request For Free Sample@


Overactive Bladder Treatment Market Research Methodology
Top-down and bottom-up approaches were used to validate the size of the global Overactive Bladder Treatment Market and estimate the size of other dependent submarkets. Various secondary sources such as associations, including American Urology Association, National Center for Biotechnology Information, U.S. National Library of Medicine, European Association of Urology, Urology Care Foundation, National Association For Continence, National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America, Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of market.

Get Sample PDF Brochure@


Market Segmentation:
By pharmacotherapies, the anticholinergics segment accounted for the largest share of the market in 2016
On the basis of pharmacotherapies, the overactive bladder treatment market is broadly segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. Anticholinergics being the first line of medical treatment on OAB accounted for the largest share of this market in 2016. Among the anticholinergics class of drugs, solifenacin accounted for the largest share of this market owing to its efficacy as compared to the other drugs of the same class.

By disease type, idiopathic bladder overactivity held the largest market share in 2016
Based on disease type of overactive bladder, the market is further categorized into idiopathic and neurogenic bladder overactivity. The neurogenic bladder overactivity segment is further categorized into Parkinson’s disease (PD), stroke, multiple sclerosis (MS), and spinal cord injury that lead to overactive bladder. In 2017, the idiopathic bladder overactivity segment is expected to account for the largest share of the bladder overactivity treatment market. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.

Key Players:
Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Will You Have Any Questions About This Report? Please Contact Us On link@


About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441